These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 21419207)

  • 1. Fast assessment of the surface distribution of API and excipients in tablets using NIR-hyperspectral imaging.
    Franch-Lage F; Amigo JM; Skibsted E; Maspoch S; Coello J
    Int J Pharm; 2011 Jun; 411(1-2):27-35. PubMed ID: 21419207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of multiple solid-state transformations at tablet surfaces using multi-series near-infrared hyperspectral imaging and multivariate curve resolution.
    Alexandrino GL; Khorasani MR; Amigo JM; Rantanen J; Poppi RJ
    Eur J Pharm Biopharm; 2015 Jun; 93():224-30. PubMed ID: 25907007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-line quantification of micronized drug and excipients in tablets by near infrared (NIR) spectroscopy: Real time monitoring of tabletting process.
    Karande AD; Heng PW; Liew CV
    Int J Pharm; 2010 Aug; 396(1-2):63-74. PubMed ID: 20558264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Content uniformity studies in tablets by NIR-CI.
    Cruz J; Blanco M
    J Pharm Biomed Anal; 2011 Sep; 56(2):408-12. PubMed ID: 21636235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blend uniformity end-point determination using near-infrared spectroscopy and multivariate calibration.
    Sulub Y; Konigsberger M; Cheney J
    J Pharm Biomed Anal; 2011 Jun; 55(3):429-34. PubMed ID: 21398064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between response surfaces for tablet characteristics of placebo and API-containing tablets manufactured by direct compression method.
    Hayashi Y; Tsuji T; Shirotori K; Oishi T; Kosugi A; Kumada S; Hirai D; Takayama K; Onuki Y
    Int J Pharm; 2017 Oct; 532(1):82-89. PubMed ID: 28859939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of the scale of segregation of low dose tablets using hyperspectral imaging.
    Ely DR; Carvajal MT
    Int J Pharm; 2011 Jul; 414(1-2):157-60. PubMed ID: 21601625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the composition of anabolic tablets using near infrared spectroscopy and Raman chemical imaging.
    Rebiere H; Ghyselinck C; Lempereur L; Brenier C
    Drug Test Anal; 2016; 8(3-4):370-7. PubMed ID: 26198290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Near-infrared chemical imaging (NIR-CI) on pharmaceutical solid dosage forms-comparing common calibration approaches.
    Ravn C; Skibsted E; Bro R
    J Pharm Biomed Anal; 2008 Nov; 48(3):554-61. PubMed ID: 18774667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAT for tableting: inline monitoring of API and excipients via NIR spectroscopy.
    Wahl PR; Fruhmann G; Sacher S; Straka G; Sowinski S; Khinast JG
    Eur J Pharm Biopharm; 2014 Jul; 87(2):271-8. PubMed ID: 24705126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of chemometric approaches for polymorphs quantification in tablets using near-infrared hyperspectral images.
    da Silva VH; Soares-Sobrinho JL; Pereira CF; Rinnan Å
    Eur J Pharm Biopharm; 2019 Jan; 134():20-28. PubMed ID: 30414499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous monitoring of API content, API distribution and crushing strength after tableting via near-infrared chemical imaging.
    Wahl PR; Pucher I; Scheibelhofer O; Kerschhaggl M; Sacher S; Khinast JG
    Int J Pharm; 2017 Feb; 518(1-2):130-137. PubMed ID: 27923700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting the dissolution behavior of pharmaceutical tablets with NIR chemical imaging.
    Yekpe K; Abatzoglou N; Bataille B; Gosselin R; Sharkawi T; Simard JS; Cournoyer A
    Int J Pharm; 2015; 486(1-2):242-51. PubMed ID: 25835268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NIR hyperspectral imaging to evaluate degradation in captopril commercial tablets.
    França Lde M; Pimentel MF; Simões Sda S; Grangeiro S; Prats-Montalbán JM; Ferrer A
    Eur J Pharm Biopharm; 2016 Jul; 104():180-8. PubMed ID: 27163244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of tablet hardness based on near infrared spectra of raw mixed powders by chemometrics.
    Otsuka M; Yamane I
    J Pharm Sci; 2006 Jul; 95(7):1425-33. PubMed ID: 16721793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A process analytical technology approach based on near infrared spectroscopy: tablet hardness, content uniformity, and dissolution test measurements of intact tablets.
    Blanco M; Alcalá M; González JM; Torras E
    J Pharm Sci; 2006 Oct; 95(10):2137-44. PubMed ID: 16883562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of diffuse transmission and reflection modes in near-infrared quantification, part 2: DIFFuse reflection information depth.
    Saeed M; Probst L; Betz G
    J Pharm Sci; 2011 Mar; 100(3):1130-41. PubMed ID: 20862671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of moisture variation on the performance of Raman spectroscopy in quantitative pharmaceutical analyses.
    Hossain MN; Igne B; Anderson CA; Drennen JK
    J Pharm Biomed Anal; 2019 Feb; 164():528-535. PubMed ID: 30458386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Transmission Raman spectroscopy and NIR Hyperspectral Imaging for the assessment of content uniformity in solid oral dosage forms
    Belay NF; Busche S; Manici V; Shaukat M; Arndt SO; Schmidt C
    Eur J Pharm Sci; 2021 Nov; 166():105963. PubMed ID: 34352284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative polymorph contaminant analysis in tablets using Raman and near infra-red spectroscopies.
    Hennigan MC; Ryder AG
    J Pharm Biomed Anal; 2013 Jan; 72():163-71. PubMed ID: 23146243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.